Core Insights - The company reported a revenue of 566 million yuan for the first half of 2025, a year-on-year decrease of 5.05%, while achieving a net profit attributable to shareholders of 47.38 million yuan, an increase of 11.75% year-on-year [1] - Despite challenges in the biopharmaceutical industry, the company maintained strategic focus and strengthened its core competitiveness, leading to stable growth in net profit and consolidation of market position [1] Group 1 - The company has optimized its market strategy for the hepatitis C market, collaborating with liver disease experts and targeting grassroots markets to enhance its market presence [1] - The market performance of its product, Kailywei, showed strong resilience during the reporting period, laying a solid foundation for future development [1] Group 2 - The company continues to maintain a leading market position for its mature products, with significant market share for Jinshuxi and Kailyin in their respective segments [2] - The construction of the antibody production base in Beijing has completed the main structure acceptance, with ongoing efficient progress in workshop purification and equipment testing [2] - The company plans to focus long-term on the field of viral and immune diseases, aiming to enhance clinical cure rates through continuous upgrades and iterations of treatment solutions [2]